Human-correlated genetic models identify precision therapy for liver cancer - Nature As proof of principle, an analysis using a suite of human-aligned immunocompetent mouse models of hepatocellular carcinoma identifies a promising therapeutic candidate, cladribine, which acts in a highly effective subtype-specific manner in combination with standard-of-care therapy.

Nature research paper: Human-correlated genetic models identify precision therapy for liver cancer

https://go.nature.com/41qNkbs

This doc was not written by NIH. It lacks thought, detail and rigor. If indirects are to change, the number should be based on a careful calculation of actual costs, not precedent from fdns who are not responsible for scientific infrastructure, and know the NIH will fill the gap

Can this cut to indirects be blocked by a judge? According to grants.nih.gov/grants/guide/n… the NIH must justify deviation from negotiated rate. Only justification given is that foundations give 10-15%. My institution blocks these because 10-15% does not cover the full cost of research

Congratulations, Bjorn!